NAD+ Infusion. The Backup Generator of Your Cells, What Science Really Knows in 2026.

There is a moment when many of my patients say almost the exact same words. "I'm still functioning. But I'm not burning anymore." They come to me with burnout, with Long Covid, after surgeries, after infections, or simply with the feeling that the last few years have aged them by a decade. They have already had their thyroid, hormones, vitamins, and iron checked. On paper, almost everything is normal. In real life, nothing is normal.

In this article, I want to introduce you to a molecule that works exactly in this gap. It's called NAD+, short for the long name nicotinamide adenine dinucleotide. You can think of NAD+ as a tiny helper molecule that sits inside every single cell of your body, where it constantly mediates between energy production, repair, and inflammation control. With age, its level can drop by half. And that may help explain why, in many people, four things start slipping at the same time. Energy, cellular repair, inflammation control, and the regulation of aging.

I will show you why NAD+ seems to help so many people subjectively, what the studies say, what they don't yet say, when an infusion makes sense for you and when it doesn't, what the procedure looks like in practice, and why certain NAD+ stories on the internet should be approached with serious skepticism. And yes, by the end, also what is really behind "growing younger," "becoming more beautiful," and "cancer protection."

What NAD+ Really Is, in Simple Terms

Picture your cells as small workshops. Most body cells contain, depending on the tissue, a few hundred to a few thousand so-called mitochondria. Red blood cells have none at all, egg cells have very many. Mitochondria are the power plants of your cells. In these workshops, sugar and fat are burned to produce energy. For this, you need a helper molecule that carries electrons, those tiny packets of energy, back and forth. That helper is NAD+.

NAD+ exists in two states. NAD+ is the empty battery. NADH is the charged battery. When food is burned, electrons jump onto NAD+, and it becomes NADH. In the so-called respiratory chain, the final step of energy production, NADH releases the electrons again and NAD+ is created anew. This happens millions of times per second in your cells. At the end of this chain stands ATP. ATP is the actual energy molecule with which your cells pay for every single action, from heartbeat to thinking to digestion.

But that is only a fraction of the story. Because NAD+ is not just an energy helper. It is also consumed by four enzyme families, that is, four groups of tiny biological machines that co-regulate your health, your repair capacity, and your pace of aging.

Four functions, a single helper molecule. When this helper goes missing, the system fails on four fronts simultaneously. That is what makes NAD+ loss so brutal. It is never just "a little less energy." It is an entire regulatory crisis inside your cells.

Why Your NAD+ Collapses. The Pathophysiology Behind Burnout, Long Covid, and Exhaustion

If you want to understand why NAD+ therapy has any clinical justification at all, you need to understand why your NAD+ pool collapses. There are four main causes, and they almost always run in parallel.

Cause 1. Inflammaging and CD38

Inflammaging is a medical term for low-grade chronic inflammation that increases with age. With every year, with every infection, with every chronic stressor, so-called senescent cells accumulate in your tissue. You can think of these cells as zombie cells. They no longer divide, but they don't die either, and they constantly emit inflammatory signaling molecules that researchers call SASP. These signaling molecules upregulate the protein CD38 in immune scavenger cells, in the cells of your blood vessel walls, and in other tissues. CD38 is the NAD+ police that breaks NAD+ down. Camacho-Pereira and colleagues described in 2016, in a mouse model, that CD38 can play a central role in age-related NAD+ loss. Covarrubias and colleagues showed in 2020, likewise largely in animal and cell models, that senescent cells can activate CD38 in scavenger cells via SASP and so lower NAD+ in tissue. In humans, this chain has not been demonstrated in the same way.

Cause 2. PARP1 Hyperactivation

Chronic oxidative stress, that is, the burden on cells from free radicals, UV radiation, toxins, alcohol, sleep deprivation, or reactivated viruses, causes constant small damage to your DNA. PARP1, the repair enzyme, kicks in every time. But the price is high. In cell models, the NAD+ supply can fall by up to 80 percent under sustained PARP1 activation. Sirtuins, which should be dampening inflammation, then have no substrate left. The mitochondria slip into a second crisis.

Cause 3. NAMPT Decline, the Drying Well

NAMPT is an enzyme that rebuilds fresh NAD+ from the metabolic byproduct nicotinamide, a kind of recycling plant inside the cell. This recycling pathway is called the salvage pathway. With advancing age, NAMPT activity could decline in several tissues. The good data on this so far come from animal and cell models; in humans the trajectory is not well studied. If it holds true, you lose two things simultaneously. More NAD+ consumption through CD38 and PARP1, less NAD+ production through declining NAMPT.

Cause 4. Mitochondrial Dysfunction. The Key Finding in Burnout, Long Covid, and Chronic Fatigue Syndrome

Chronic fatigue syndrome, known in the literature as ME/CFS, is biochemically very similar to what we find in Long Covid and severe burnout. A 2025 paper in Cell Reports Medicine showed in these patients a reduced ratio of ATP to its energy-poor sibling ADP, that is, less charged battery per cell. It also showed a shift away from efficient energy generation in the mitochondria toward an emergency mode called glycolysis, which runs without oxygen but yields far less energy. And it showed a disturbance of the kynurenine pathway, an important metabolic route along which the amino acid tryptophan is converted into NAD+. A review in Physiology 2025 summarizes that the protein WASF3 directly destabilizes the components of the respiratory chain. This is one cellular perspective on burnout. Exhaustion is not only "in your head." At the level of the mitochondria, a real energy crisis can be described. Whether it comes first or follows the exhaustion has not been scientifically settled.

Burnout, Retold. What Actually Happens in Your Cells

When I work with burnout patients, my first picture is often that of an overloaded control center. The HPA axis, that is, the stress axis between the hypothalamus and pituitary in the brain and the adrenals, the small hormone glands above your kidneys, runs in the red for months or years. Cortisol, the most important stress hormone, is either too high in the morning or, in later phases, paradoxically lowered. Sleep becomes shallow. Digestion slows. The vagus, your central calming nerve that down-regulates breathing, heart rate, and digestion, retreats. And in the cells, the following happens.

• Mitochondria can reduce their number and function. Individual studies in burnout patients describe reduced energy production in immune cells.
• The NAD+ pool can drop through chronic activation of PARP1 and CD38.
• Sirtuin activity can collapse. SIRT1 is then less able to dampen the inflammation switch NF-kappa B. Low-grade inflammation can rise.
• Tryptophan, an amino acid from your food and a precursor of serotonin, the most important mood neurotransmitter, can be redirected under stress into the kynurenine pathway. Instead of serotonin, metabolites such as quinolinic acid can then arise in greater quantity, and they may place an additional burden on the brain.
• The brain's nightly cleaning system, the glymphatic system, can become sluggish. Sleep architecture can suffer. Brain fog, that feeling of thinking as if under a glass dome, then becomes an everyday experience.

NAD+ is interesting in precisely this constellation because it can act at several points simultaneously. It supplies substrate for the respiratory chain, reactivates the sirtuins, dampens the inflammation switch NF-kappa B indirectly via SIRT1, and it supports the formation of NADPH, a variant that regenerates the body's most important antioxidant, glutathione, and in this way neutralizes free radicals. NAD+ is a multitool. That is precisely its clinical appeal.

What the Studies Actually Show. A Differentiated Evidence Table 2026

This is the most honest part. I divide the evidence into three tiers so you can judge for yourself what is better supported and what is promising but still thin.

Two things need to be read alongside it. First, almost the entire body of evidence was generated with oral NAD+ precursors, that is, NMN and NR as a capsule, and not with the infusion. These results cannot simply be transferred to an infusion. Second, none of these studies is large. The tiers below are my personal assessment of the data and not an official appraisal by a medical society.

The Key Studies in Detail

Heart and Circulation. Why NAD+ Is So Compelling Cardiologically

The heart is among the organs with the highest energy turnover per gram of tissue. It beats about 100,000 times per day, turning over many times its own weight in energy currency. A healthy heart depends on intact mitochondria, that is, fully functional power plants. In heart failure, these mitochondria are weakened. They produce less ATP, that is, less energy per second, and more oxygen radicals, that is, harmful metabolic byproducts. This is exactly where NAD+ comes in.

This does not mean NAD+ replaces the established cardiac medications, that is, statins for cholesterol lowering, ACE inhibitors and beta blockers for blood pressure, or the newer SGLT2 inhibitors for heart failure. But it can be an additional axis, especially in patients with metabolically driven heart disease who continue to suffer despite standard therapy. Whether the combination of NAD+ supplementation and standard cardiac therapy delivers anything in the end cannot be derived from a single trial. If at all, it belongs in coordination with the treating cardiologist. And this matters most: prescribed cardiac medications are never stopped or reduced on your own.

Brain and Mood. When Thinking Becomes Clear Again

The human brain accounts for about 2 percent of body weight but consumes about 20 percent of total energy. Measured by the ratio of weight to energy demand, it is therefore among the most demanding organs in the body. When the mitochondria in nerve cells come under pressure, concentration, mood, sleep, and stress resilience all suffer. NAD+ intervenes here at multiple points.

Brain Fog Is Not a Made-Up Problem

Imaging studies in Long Covid and chronic fatigue syndrome show reduced glucose metabolism in the front regions of the brain that are responsible for concentration and planning. Whether this is the cause of the fog in the head or an accompanying phenomenon cannot be derived from it. All that is certain is that there is a measurable finding that goes along with it. The feeling is not imagined. NAD+ can support the respiratory chain in nerve cells and their support cells, the astrocytes, via the protective enzyme SIRT3. In the NADPARK study, a phase I trial in 30 people, the NAD+ level was measured directly in the living brain, using a specialized form of magnetic resonance, phosphorus MR spectroscopy. After NR administration, the level rose measurably, though to varying degrees. In those with the strongest rise in the brain, the authors describe a mild clinical improvement at the same time. The study was designed as a safety trial and explicitly not to demonstrate a clinical benefit. I therefore classify it as weak evidence.

Mood and Drive

SIRT1 can also act on switching points in the dopaminergic pathway, that is, the nerve pathways that work with the messenger dopamine and control drive, joy, and motivation. In animal studies, NAD+ deficiency in the front of the brain led to depressive behavior. In humans, the data are considerably thinner and direct evidence is lacking. In the 2025 Long Covid study, depressive symptoms improved after 10 weeks of NR compared with baseline. That was a supplementary analysis, not a primary result.

Neurodegeneration

In Parkinson's, Alzheimer's, and the motor neuron disease ALS, several investigations have found indications of a disturbed NAD+ metabolism. With NOPARK, a larger study in around 400 Parkinson's patients is ongoing. The hypothesis is that an NAD+ precursor could slow the course of the disease. This is not proven. The mechanistic plausibility is good, and as long as robust results are missing, NAD+ in these diseases is a research question and not a treatment.

Tumor and Cancer. Here Things Get Delicate

NAD+ and cancer is one of the most exciting and at the same time most sensitive topics. Two extreme positions circulate online. Some claim NAD+ protects against cancer. Others warn that NAD+ feeds tumors. The data are more complex than either camp, and honestly, two-edged.

What Is Cited in the Debate in Favor of a Protective Effect

NAD+ activates the DNA repair machinery, that is, PARP1 and the sirtuins. Intact DNA repair could slow the accumulation of mutations. The ONTRAC study from 2015 is regularly cited at this point. It studied 386 people who already had at least two non-melanoma skin tumors within five years, that is, explicitly high-risk patients and not healthy people. Oral nicotinamide in tablet form lowered the rate of new tumors there by 23 percent. Two things belong with this: after discontinuation, no benefit was detectable any more, and what was studied was a different molecule in a different form of administration. Nothing from this can be transferred to an NAD+ infusion. On the treatment of cancer disease I do not comment in a public text.

What Argues for Caution in the Tumor Case

Tumor cells have a massively increased NAD+ demand. They use it for their own rapid proliferation. There is even an entire class of cancer drugs in clinical development, so-called NAMPT inhibitors, which do exactly the opposite of NAD+ therapy. They block the NAD+ supply in tumor cells in order to halt their growth. For exactly this reason, NAD+ supplementation is contraindicated in active cancer disease, except in close coordination with oncology, that is, the medical specialty for cancer.

The Important Differentiation

Both stand side by side, and both are unproven. A protective effect in healthy people is a hypothesis, supported by mechanisms and by the ONTRAC data on oral nicotinamide. An unfavorable effect in an existing tumor disease is likewise conceivable on the basis of tumor biology. What matters is the context, that is, the state of the body into which the molecule is given. As long as this is unresolved, restraint applies.

Longevity. What We Really Know About Biological Age and NAD+

Longevity is the buzzword of recent years. Behind the term lies a very concrete question. Can you extend the time you spend in good health, the so-called healthspan? And can you become biologically younger, measured with modern blood-test markers such as the epigenetic clock or telomere length?

What Are Biological Age Markers

What Can NAD+ Deliver on This Axis

At the level of biological mechanisms, the plausibility is high. NAD+ activates sirtuins, which in turn can alter chemical markings on the DNA and so influence gene expression and methylation patterns. NAD+ supports PARP1-dependent repair, which could slow the shortening of telomeres. NAD+ could dampen inflammaging and thereby favorably influence inflammation values such as hs-CRP and IL-6. In animal studies, NAD+ supplementation extended lifespan and improved epigenetic markers. In humans, none of these steps is established. In humans, large studies of this kind are still being built. First observational studies suggest that NMN as an oral precursor can improve inflammation markers and markers of vascular aging.

What We Don't Yet Know

There is currently no large endpoint RCT showing that NAD+ precursors measurably reverse the epigenetic clock in a broad population. In smaller studies there have been signals, in others none. We are in an exciting phase in which the concept is biologically very plausible, but the number of hard clinical endpoints is still growing.

Becoming More Beautiful. Skin, Hair, Collagen. What's Possible, What Isn't

Here is the honest layout. Two areas have data, one does not yet.

Hair. There Is First Real Data

The 2025 Cosmetics study from Tokyo is very small, only 15 women, and it comes from the environment of an NMN manufacturer. 500 mg of oral NMN over 12 weeks. The density of growing hairs in the anagen phase, that is, the active growth phase of a hair, rose by 57 percent. The density of fully developed terminal hairs rose by 71 percent. Hair thickness increased. Percentages like these sound spectacular, but here they come from a handful of participants, and that is not a demonstration of efficacy. Mechanistically, that fits with what we know about NAD+ and stem cells, that is, the mother cells from which new cells emerge, in the growth environment of the hair follicle. SIRT1 and SIRT3 protect these stem cells, NAD+ supplies the energy for the anagen phase.

Skin. Mechanism Strong, Clinical Human Data Limited

In mouse studies and cell cultures, NMN shows clear effects on the skin barrier, on collagen type I, the most important structural protein of the skin which gives it firmness, on UV protection, and on wound healing. A 2025 paper showed improved skin structure and reduced wrinkle formation in mice. In humans, large studies still missing that cleanly measure purely cosmetic endpoints such as wrinkles and elasticity. What we do have are studies on nicotinamide, a close relative. Those works had dermatological endpoints in high-risk patients. They say nothing about wrinkles, glow, or elasticity.

Collagen and Connective Tissue

SIRT1 regulates the activity of fibroblasts, the connective tissue cells that produce collagen. NAD+ is an additionally required helper molecule in this reaction. Under oxidative stress, one of the drivers of collagen breakdown, NAD+ could have a supportive effect. Direct clinical studies on wrinkle reduction are missing.

Metabolism, Weight, Insulin

Yoshino and colleagues showed in a paper published in Science in 2021 that NMN can increase the insulin sensitivity of muscle cells in prediabetic women, that is, women with a precursor stage of type 2 diabetes, by about 25 percent. Insulin sensitivity describes how well your cells respond to the hormone insulin and take up sugar from the blood. The effects on fasting blood sugar and HbA1c, the long-term blood sugar value over the past three months, were mixed in follow-up studies. That fits with what we know mechanistically. NAD+ activates SIRT1 and SIRT3, which can make the mitochondria more efficient. It can improve the utilization of free fatty acids, that is, the fat building blocks in the blood. It can contribute to metabolic reorganization in fatty liver, that is, a pathological accumulation of fat in the liver.

NAD+ is not a weight-loss drug. But it can be a building block in a holistic program for metabolically burdened patients, a program made of time-structured nutrition, strength training, sleep hygiene, and stress regulation.

Immune System and Chronic Inflammation

The protective enzyme SIRT1 deacetylates, that is, removes a chemical marking from, a component of NF-kappa B. NF-kappa B is the central switch for inflammation genes in the cell nucleus. By resetting this switch, SIRT1 can dampen the production of inflammatory messengers. Without sufficient NAD+, this works less well. NF-kappa B then runs less dampened, and inflammation values such as IL-6, TNF-alpha, and CRP can rise. This is a well-founded model for inflammaging.

Clinically, the Elhassan study from 2019 shows that oral NR over 21 days can lower IL-6 and TNF-alpha and upregulate the activity of inflammation-suppressing genes in muscle. In the Werner syndrome crossover trial in 2025, arterial stiffness, the skin ulcers, and the creatinine value improved. The work makes no statement about inflammation markers.

When Does an NAD+ Infusion Make Clinical Sense

I do not go by hype indications. I go by pathophysiology and individual situation. Here are the profiles in which, in my view, an NAD+ strategy is worth discussing at all. This is my clinical assessment, not an assurance that it will work for you.

High Plausibility

I deliberately leave Post Covid and Long Covid out of this overview. On notifiable infectious diseases and their sequelae I am not permitted to make public statements involving treatment offers. If this affects you, please speak to me directly.

• Burnout after a prolonged high-stress phase, with classic mitochondrial markers
• Reactivated chronic infections, such as a flare-up of the Epstein-Barr virus, which many people once experienced as glandular fever, with persistent exhaustion
• Recovery phase after surgery or a severe illness
• Early neurodegenerative burden with subjective sense of cognitive decline
• Heart failure adjunctive therapy in coordination with cardiology
• Werner syndrome or other models of accelerated aging
• Chronic inflammatory constellations with elevated hs-CRP and IL-6

Moderate Plausibility

• Targeted longevity approach in people with objective cellular-aging markers
• Recovery in performance-oriented people with overdosed loading
• Improvement of skin and hair as a secondary effect within a broader program
• ADHD-like exhaustion with a dominant mitochondrial component

Of Little Use or Contraindicated

• Pure lifestyle boosting without indication and without diagnostics
• Active cancer disease without clearance from the treating oncologist
• Pregnancy and breastfeeding. Insufficient data
• Severe kidney insufficiency or liver disease
• Uncontrolled high blood pressure, acute cardiac decompensation
• Known severe niacin intolerance or severe allergic reactions in the medical history
• Children and adolescents under 18. There are no data on this
• Known glucose-6-phosphate dehydrogenase deficiency, G6PD deficiency for short, if high-dose vitamin C or glutathione is to be given alongside. Red blood cells can break down in that case. This deficiency belongs ruled out in the lab beforehand
• Impaired kidney function or a history of kidney stones, if high-dose intravenous vitamin C is being considered. Oxalate can deposit in the kidney

For intravenous NAD+ there are no systematic interaction studies. In my view, restraint is warranted wherever the mechanism could run in the opposite direction. That includes the prescription-only PARP inhibitors from cancer therapy and the NAMPT inhibitors so far used only in clinical trials, which deliberately throttle the NAD+ supply of tumor cells, and also cytostatics in general and immunosuppressants after a transplant. That is a physiological consideration and not a study finding. Whether a combination is tolerable is always decided by the treating specialty.

What the Process Looks Like in My Practice

I will describe the complete path, from the first history-taking, that is, the initial medical conversation in which your medical history is recorded, through to the maintenance phase, so you know exactly what to expect.

Safety, Side Effects, What You Need to Know

NAD+ is an active molecule. That is its appeal and its risk in equal measure. Two things you need to know before you read the table. First, NAD+ for infusion is not an approved medicinal product in Germany. There is therefore no officially reviewed prescribing information, no verified frequency data on side effects, and no robust data on long-term safety. Second, for exactly that reason the entries below are not official side-effect rates, but what is described in small investigations and in practice. No one can rule out rare and serious reactions for you.

What NAD+ CANNOT Do. The Honest Differentiation

• NAD+ is not an antidepressant. In moderate to severe depression, psychotherapy and where indicated pharmacotherapy remain the first line. If you are in a crisis or having thoughts of taking your own life, please get help immediately. In Germany, Telefonseelsorge is available free of charge around the clock on 0800 111 0 111, and in an emergency call 112.
• NAD+ does not replace clean thyroid diagnostics, evaluation of nighttime breathing pauses, or hormone substitution.
• NAD+ does not make you young. It can modulate cellular aging processes. It is not a fountain of youth.
• With merely mild fatigue I would start with lifestyle first. Whether oral NAD+ precursors contribute anything there is open. In the only controlled trial with fatigue as an endpoint, there was no difference from placebo.
• NAD+ does not work without a lifestyle foundation. Sleeping poorly, smoking, drinking heavily, eating industrial food, barely moving. Those who keep all of that in place will achieve little with NAD+ either.
• NAD+ does not protect against cancer. In an active tumor disease it is not indicated. In healthy people there are hypotheses, nothing more.

My Medical Conclusion

NAD+ is not a hype molecule. But it is also not a miracle drug. In my view it is one of the biologically best-founded cellular tools when the indication is right. Well-founded does not mean proven. I always practice according to the same principles.

• Understanding before prescribing. You should know why NAD+ makes sense in your situation, or why it doesn't.
• Diagnostics before infusion. No NAD+ therapy without history-taking, lab work, and an individual concept.
• Slow, careful, medically supervised. Safe in the sense of officially reviewed is not something I can call it; the data for that are missing.
• In an overall context. NAD+ is one building block in a plan made of sleep, nutrition, exercise, stress regulation, hormone balance, and micronutrients.
• Differentiated expectations. Not every person benefits equally. We discuss this openly.

If you have been feeling for months or years that your batteries no longer charge properly, and if classic diagnostics do find some abnormalities but no full explanation, it is worth taking the mitochondrial level seriously. NAD+ is one of the most interesting approaches we currently have at this level. It is not for everyone, and no one knows in advance whether it will change anything for you. The physiology behind it is well founded. But a good mechanism is not yet proof of efficacy, and I do not want to keep that difference from you.

Frequently Asked Questions

This article is general health information and not advertising for a medicinal product. It does not replace a medical examination, a diagnosis, or individual advice. NAD+ for infusion is not an approved medicinal product in Germany. Whether an application is justifiable in your situation can only be decided after a personal examination and full information. Never stop prescribed medication on your own. As of April 2026.